Evaluation of PDZD11 in hepatocellular carcinoma: prognostic value and diagnostic potential in combination with AFP
BackgroundHepatocellular carcinoma (HCC) is the most prevalent liver cancer, with a 5-year survival rate below 20% and an average survival time of 3-6 months. Identifying new biomarkers is crucial for early diagnosis and prognosis. The function of PDZ domain protein 11 (PDZD11) in HCC remains unclea...
Saved in:
| Main Authors: | Yiyun Ni, Bin Liu, Weizhen Zhang, Yilin Pang, Yaling Tian, Qingsong Lv, Shengwen Shi, Yang Zheng, Huihui Fan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1533865/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Trajectories of α-fetoprotein and unresectable hepatocellular carcinoma outcomes receiving lenvatinib: a retrospective, multicenter cohort study
by: Yitao Zheng, et al.
Published: (2025-07-01) -
circ_0020123 promotes cell proliferation and migration in lung adenocarcinoma via PDZD8
by: Wei Wei, et al.
Published: (2022-03-01) -
Updating AFP Level in Chronic Hepatitis B to Evaluate the Risk of Hepatocellular Carcinoma Occurrence
by: Juferdy Kurniawan, et al.
Published: (2024-10-01) -
Updating AFP Level in Chronic Hepatitis B to Evaluate the Risk of Hepatocellular Carcinoma Occurrence
by: Juferdy Kurniawan, et al.
Published: (2024-07-01) -
Combining AFP, PIVKA-II, and GP73 has diagnostic utility for hepatitis B-associated hepatocellular carcinoma and is consistent with liver pathology results
by: Hu Rui, et al.
Published: (2025-04-01)